Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works against multidrug-resistant strains, potentially inspiring improved treatments and drug development ...

Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based ...

Pangenomes are collections of annotated genome sequences of multiple individuals of a species. The structural variants ...

enzyme-linked immunosorbent assay (ELISA) solutions, and Western blot tests worldwide. Founded in 1993 by histologist Steven ...

About Invizyne Technologies, Inc. Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company ...

Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to ...

The goal is to refine these technologies to achieve superior degradation rates, employing cutting-edge materials and approaches such as metal oxide nanoparticles, enzyme-immobilized systems, and ...

5.2 The impugned goods are for testing of food and not for diagnostic purposes of human beings (including animals). Main ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...